CO2018011133A2 - Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado - Google Patents

Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado

Info

Publication number
CO2018011133A2
CO2018011133A2 CONC2018/0011133A CO2018011133A CO2018011133A2 CO 2018011133 A2 CO2018011133 A2 CO 2018011133A2 CO 2018011133 A CO2018011133 A CO 2018011133A CO 2018011133 A2 CO2018011133 A2 CO 2018011133A2
Authority
CO
Colombia
Prior art keywords
nipple
involution
accelerate
drying
chitosan solution
Prior art date
Application number
CONC2018/0011133A
Other languages
English (en)
Inventor
Pierre Lacasse
Samuel Lanctôt
Patrick Fustier
Ali R Taherian
Barbara Bisakowski
Original Assignee
Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food filed Critical Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food
Publication of CO2018011133A2 publication Critical patent/CO2018011133A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un método para prevenir infección intramamaria y acelerar la involución mediante administrar un modificador de la respuesta biológica, específicamente una solución de quitosano, al pezón de un mamífero en lactación durante el secado. Una solución de quitosano neutralizada con una base débil tal como β-glicerofosfato puede permanecer líquida a temperatura ambiente para ser inyectada dentro de un pezón, pero puede formar un hidrogel a la temperatura del cuerpo dentro del pezón. La solución de quitosano neutralizada puede también ser opcionalmente co-administrada con un sellante de pezones.
CONC2018/0011133A 2016-03-18 2018-10-17 Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado CO2018011133A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662310025P 2016-03-18 2016-03-18
PCT/CA2017/050339 WO2017156632A1 (en) 2016-03-18 2017-03-16 Chitosan hydrogels for accelerating involution and preventing infection of the mammary gland at drying-off

Publications (1)

Publication Number Publication Date
CO2018011133A2 true CO2018011133A2 (es) 2018-10-31

Family

ID=59850126

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0011133A CO2018011133A2 (es) 2016-03-18 2018-10-17 Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado

Country Status (11)

Country Link
US (1) US10828319B2 (es)
EP (1) EP3429601A4 (es)
CN (1) CN109310705A (es)
AU (1) AU2017233727A1 (es)
BR (1) BR112018068794A2 (es)
CA (1) CA3015846A1 (es)
CL (1) CL2018002562A1 (es)
CO (1) CO2018011133A2 (es)
MX (1) MX2018011350A (es)
RU (1) RU2018135961A (es)
WO (1) WO2017156632A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7123971B2 (ja) * 2017-04-20 2022-08-23 ゾエティス・サービシーズ・エルエルシー 乳腺炎を処置する際に使用する動物用組成物、及び関連方法
BR112022010385A2 (pt) 2019-11-28 2022-08-23 Boehringer Ingelheim Vetmedica Gmbh Uso de inibidores de sglt-2 na secagem de mamíferos não humanos
CN111840212B (zh) * 2020-06-18 2023-07-21 余祖功 一种非人类动物用乳头封闭剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
EP1448607B1 (en) 2001-11-15 2011-01-05 Biosyntech Canada Inc. Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
WO2015093937A1 (en) * 2013-12-19 2015-06-25 N.V. Nutricia Lactobacillus salivarius for the treatment of mastitis
PT3370698T (pt) * 2015-11-03 2022-03-02 Zoetis Services Llc Compósitos de polímero sol-gel e utilizações dos mesmos

Also Published As

Publication number Publication date
BR112018068794A2 (pt) 2019-04-09
RU2018135961A (ru) 2020-04-20
WO2017156632A1 (en) 2017-09-21
US10828319B2 (en) 2020-11-10
EP3429601A4 (en) 2019-11-27
MX2018011350A (es) 2019-06-06
CL2018002562A1 (es) 2019-02-15
EP3429601A1 (en) 2019-01-23
AU2017233727A1 (en) 2018-09-13
CN109310705A (zh) 2019-02-05
CA3015846A1 (en) 2017-09-21
US20190060352A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
WO2017163132A3 (en) Use of umbilical cord blood derived exosomes for tissue repair
CO2018011133A2 (es) Método para acelerar la involución e impedir la infección de glándulas mamarias en el secado
BR112017023516A2 (pt) composição de polímero reforçado com fibra, e, artigo.
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
MX2015008685A (es) Tratamiento de artritis psoriasica usando apremilast.
ES2533145R1 (es) Procedimiento cosmético para reducir el tejido adiposo subcutáneo
EA201591761A1 (ru) Композиции на основе наночастиц
CO7190239A2 (es) Dialisato a base de polímero
MX2016011682A (es) Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
CO6500125A1 (es) Suministro de curcumina por derivacion
IN2014KN02617A (es)
PE20171497A1 (es) Conector liberable para soportar un conducto flexible
IN2014DE02615A (es)
CL2012002176A1 (es) Procedimiento de apertura facil de un operculo termo sellado sobre el pico de un recipiente de vidrio y recipiente correspondiente, en donde las fuerzas de arranque inicial y final son como máximo de 30 n, en un jalado del opérculo a 90º a una velocidad de 300 mm/min; pote o recipiente equivalente de vidrio; y aplicación de dicho procedimiento.
BR112018008181A2 (pt) baclofen intravenoso e métodos de tratamento
RU2014103878A (ru) Способ лечения послеродовой субинволюции матки
TWM533069U (en) A device of preparing cell block
UA112524U (xx) Спосіб лікування генералізованого пародонтиту хронічного перебігу
BR112018012865A8 (pt) Sistema e método para aumentar uma área transversal de um lúmen corporal
UA114893U (uk) Спосіб ендоскопічної репараторно-гемостатичної ін'єкційної терапії шлунково-кишкових кровотеч
UA97313U (en) Method for the treatment of severe delirium tremens
UA107884U (uk) Спосіб інтенсивного лікування раку крові
UA108139U (uk) Спосіб терапії корів з ендометритом, як профілактика гонадопатій